EUVIMEDEUVIMED entdecken
Crossref

In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment

Matilde Bocci, Aureliano Zana, Lucrezia Principi, Laura Lucaroni, Luca Prati, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli, Andrea Galbiati

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Matilde Bocci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: matilde.bocci@philochem.ch. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule-drug conjugates (SMDCs) are increasingly considered as a therapeutic alternative to antibody-drug conjugates (ADCs) for cancer therapy. OncoFAP is an ultra-high affinity ligand of Fibroblast Activation Protein (FAP), a stromal tumor-associated antigen overexpressed in a wide variety of solid human malignancies. We have recently reported the development of non-internalizing OncoFAP-based SMDCs, which are activated by FAP thanks to selective proteolytic cleavage of the -GlyPro- linker with consequent release of monomethyl auristatin E (MMAE) in the tumor microenvironment. In this article, we describe the generation and the in vivo characterization of FAP-cleavable OncoFAP-drug conjugates based on potent topoisomerase I inhibitors (DXd, SN-38, and exatecan) and an anti-tubulin payload (MMAE), which are already exploited in clinical-stage and approved ADCs. The Glycine-Proline FAP-cleavable technology was directly benchmarked against linkers found in Adcetris™, Enhertu™, and Trodelvy™ structures by means of in vivo therapeutic experiments in mice bearing tumors with cellular or stromal FAP expression. OncoFAP-GlyPro-Exatecan and OncoFAP-GlyPro-MMAE emerged as the most efficacious anti-cancer therapeutics against FAP-positive cellular models. OncoFAP-GlyPro-MMAE exhibited a potent antitumor activity also against stromal models, and was therefore selected for clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunoconjugatesHumansAnimalsMicePharmaceutical PreparationsTubulinTumor MicroenvironmentCamptothecinCell Line, Tumor

Stichwörter der Autor:innen

Cytotoxic payloadsFAPIn vivo activationSmall molecule-drug conjugatesTargeted therapy

Substanzen

Antineoplastic AgentsPharmaceutical PreparationsTubulinImmunoconjugatesCamptothecin

Autor:innen und Institutionen

  • Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: matilde.bocci@philochem.ch.
  • Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland.
  • Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, Zurich CH-8093, Switzerland; Philogen S.p.A., Siena 53100, Italy.
  • Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: samuele.cazzamalli@philochem.ch.
  • Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: andrea.galbiati@philochem.ch.

Zitieren

APA

Bocci, M., Zana, A., Principi, L., Lucaroni, L., Prati, L., Gilardoni, E., Neri, D., Cazzamalli, S., & Galbiati, A. (2024). In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.014

Vancouver

Bocci M, Zana A, Principi L, Lucaroni L, Prati L, Gilardoni E, et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.014

BibTeX
@article{Bocci2024,
  author = {Bocci, Matilde and Zana, Aureliano and Principi, Lucrezia and Lucaroni, Laura and Prati, Luca and Gilardoni, Ettore and Neri, Dario and Cazzamalli, Samuele and Galbiati, Andrea},
  title = {In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.02.014}
}
Kostenlos starten →